BB Biotech Balance Sheet Health
Financial Health criteria checks 4/6
BB Biotech has a total shareholder equity of CHF2.2B and total debt of CHF274.3M, which brings its debt-to-equity ratio to 12.3%. Its total assets and total liabilities are CHF2.5B and CHF277.2M respectively. BB Biotech's EBIT is CHF12.6M making its interest coverage ratio 2.2. It has cash and short-term investments of CHF2.5B.
Key information
12.3%
Debt to equity ratio
CHF 274.30m
Debt
| Interest coverage ratio | 2.2x |
| Cash | CHF 2.51b |
| Equity | CHF 2.23b |
| Total liabilities | CHF 277.23m |
| Total assets | CHF 2.51b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: BIONZ's short term assets (CHF2.5B) exceed its short term liabilities (CHF277.2M).
Long Term Liabilities: BIONZ has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: BIONZ has more cash than its total debt.
Reducing Debt: BIONZ's debt to equity ratio has increased from 7.8% to 12.3% over the past 5 years.
Debt Coverage: BIONZ's debt is well covered by operating cash flow (53.3%).
Interest Coverage: BIONZ's interest payments on its debt are not well covered by EBIT (2.2x coverage).